echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Brain: Scientists have revealed a molecular link between inflammation and Parkinson's disease.

    Brain: Scientists have revealed a molecular link between inflammation and Parkinson's disease.

    • Last Update: 2020-10-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    12, 2020 // -- In a recent study published in the international journal Brain, scientists from the University of Luxembourg and other institutions revealed a link between inflammation and specific genetic mutations in the body of patients with Parkinson's disease.
    About 15% of Parkinson's disease cases are related to known genetic backgrounds, with mutations in the Parkin and PINK1 genes being the most common causes, so revealing the cellular mechanisms altered by genetic mutations may be important for developing new therapeutic tools, researchers said in the study. Analysis of the serums of 245 participants in two separate studies found increased levels of mitochondrial DNA (mtDNA) and interlebinin 6 (IL-6) circulating in the body of patients with mutations in the Parkin or PINK1 gene.
    Photo Source: University of Luxembourg Researchers Point out that the absence of Parkin or PINK1 proteins may lead to impaired mitochondrial autophagy, and abnormal mitochondrial levels induce the release of mitochondrial DNA, which induces inflammation and increases the patient's machine Levels of IL-6 in the body's blood, when reached in the brain, are thought to play a crucial role in the development of neurodegenerative diseases, and the results of this paper suggest that anti-inflammatory drugs are used to treat or hopefully slow the progression of the disease in patients with Parkinson's disease.
    By studying the differences between patients carrying Parkin or PINK1 gene mutations on one chromosome (hybrid) or two chromosomes, the researchers found that detecting levels of systemic inflammation in the patient's blood or as a special biomarker indicating the genetic form of these Parkinson's diseases showed higher levels of IL-6 in both chromosomes than in patients with mutations on both chromosomes, but higher levels in patients with hybrids compared to healthy control populations. Levels of IL-6 in the body have also increased significantly, which may indicate that hemp mutations may form a strong risk factor for early Parkinson's disease, and even before these hybrid carrier diseases occur, researchers can detect disease at an early stage by monitoring levels of IL-6 in their body serum, similarly, circulating gland DNA levels or as an effective indicator of the progression of disease in hybrid Parkin/PINK1 mutants.
    The study has potential clinical application value and significance by detecting biomarkers present in the patient's body serum or helping to indicate the progression of the disease, and the findings are expected to help researchers develop new therapies that target patients with Parkin/PINK1-related congenital immunological responses, said Grünewald, a researcher.
    () Original source: Max Borsche, Inke R König, Sylvie Delcambre, et al. Mitochondrial damage-associated highlights biomarkers in PRKN/PINK1 Parkinsonism, Brain (2020). DOI: 10.1093/brain/awaa246.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.